Secretory leukocyte peptidase inhibitor and lung cancer

Cancer Science

Volumn 99, Issue 5, 2008, Pages 849-855

  Nukiwa, Toshihiro ^a   Suzuki, Takuji ^a   Fukuhara, Tatsuro ^a   Kikuchi, Toshiaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; E1A PROTEIN; ELASTASE INHIBITOR; NK4 PROTEIN; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RECOMBINANT SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SIVELESTAT;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; CANCER GENE THERAPY; CANCER INVASION; CHEMICAL CARCINOGENESIS; CHROMOSOMAL LOCALIZATION; CHROMOSOME 20Q; CYSTIC FIBROSIS; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MICROARRAY ANALYSIS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TISSUE REPAIR; UPREGULATION; VIRAL GENE THERAPY; VIRUS TRANSMISSION; AMINO ACID SEQUENCE; ANIMAL; BIOLOGICAL MODEL; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; INFLAMMATION; LUNG TUMOR; METABOLISM; MOLECULAR GENETICS; MOUSE; MOUSE MUTANT;

AMINO ACID SEQUENCE; ANIMALS; DOWN-REGULATION; HIV; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR;

EID: 43649096718     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00772.x     Document Type: Review

References (45)

1. Abe T, Kobayashi N, Yoshimura K et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 1991; 87: 2207-15.
2. Weldon S, McGarry N, Taggart CC, McElvaney NG. The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses. Biochem Soc Trans 2007; 35: 273-6.
3. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun 2005; 73: 1271-4.
4. Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997; 88: 417-26.
5. Gruber MP, Coldren CD, Woolum MD et al. Human lung project: Evaluating variance of gene expression in the human lung. Am J Respir Cell Mol Biol 2006; 35: 65-71.
6. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 167-74.
7. Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al. Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63: 8614-22.
8. Taggart CC, Cryan SA, Weldon S et al. Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202: 1659-68.
9. Abe T, Tominaga Y, Kikuchi T et al. Bacterial pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung. Am J Respir Crit Care Med 1997; 156: 1235-40.
10. Kikuchi T, Abe T, Satoh K et al. Cis-acting region associated with lung cell-specific expression of the secretory leukoprotease inhibitor gene. Am J Respir Cell Mol Biol 1997; 17: 361-7.
11. Kikuchi T, Abe T, Hoshi S et al. Structure of the murine secretory leukoprotease inhibitor (Slpi) gene and chromosomal localization of the human and murine SLPI genes. Am J Respir Cell Mol Biol 1998; 19: 875-80.
12. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002; 368: 233-42.
13. Hurle B, Swanson W, Green ED. Comparative sequence analyses reveal rapid and divergent evolutionary changes of the WFDC locus in the primate lineage. Genome Res 2007; 17: 276-86.
14. Hagiwara K, Kikuchi T, Endo Y et al. Mouse SWAM1 and SWAM2 are antibacterial proteins composed of a single whey acidic protein motif. J Immunol 2003; 170: 1973-9.
15. Ashcroft GS, Lei K, Jin W et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000; 6: 1147-53.
16. Zhu J, Nathan C, Jin W et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111: 867-78.
17. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996; 64: 4520-4.
18. Couto MA, Harwig SS, Cullor JS, Hughes JP, Lehrer RI. eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes. Infect Immun 1992; 60: 5042-7.
19. Couto MA, Harwig SS, Lehrer RI. Selective inhibition of microbial serine proteases by eNAP-2, an antimicrobial peptide from equine neutrophils. Infect Immun 1993; 61: 2991-4.
20. Ma G, Greenwell-Wild T, Lei K et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004; 200: 1337-46.
21. McElvaney NG, Nakamura H, Birrer P et al. Modulation of airway inflammation in cystic fibrosis. In.vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992; 90: 1296-301.
22. Nakamura A, Mori Y, Hagiwara K et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med 2003; 197: 669-74.
23. Lentsch AB, Jordan JA, Czermak BJ et al. Inhibition of NF-κB activation and augmentation of IκBβ by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999; 154: 239-47.
24. Xu W, He B, Chiu A et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol 2007; 8: 294-303.
25. Greene CM, McElvaney NG, O'Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004; 72: 3684-7.
26. Sano C, Shimizu T, Sato K, Kawauchi H, Tomioka H. Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-β), by lipopolysaccharide-stimulated macrophages. Clin Exp Immunol 2000; 121: 77-85.
27. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997; 99: 894-900.
28. Rosen EM, Knesel J, Goldberg ID et al. Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer 1994; 57: 706-14.
29. Kikuchi T, Abe T, Yaekashiwa M et al. Secretory leukoprotease inhibitor augments hepatocyte growth factor production in human lung fibroblasts. Am J Respir Cell Mol Biol 2000; 23: 364-70.
30. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem 2002; 277: 29.999-30.009.
31. Devoogdt N, Revets H, Ghassabeh GH, De Baetselier P. Secretory leukocyte protease inhibitor in cancer development. Ann NY Acad Sci 2004; 1028: 380-9.
32. Israeli O, Goldring-Aviram A, Rienstein S et al. In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet 2005; 160: 35-42.
33. Ameshima S, Ishizaki T, Demura Y, Imamura Y, Miyamori I, Mitsuhashi H. Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma. Cancer 2000; 89: 1448-56.
34. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-7.
35. Maemondo M, Saijo Y, Narumi K et al. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res 2004; 64: 4611-20.
36. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60: 6737-43.
37. Schlingemann J, Hess J, Wrobel G et al. Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. Int J Cancer 2003; 104: 699-708.
38. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003; 100: 5778-82.
39. Kluger HM, Chelouche Lev D, Kluger Y et al. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res 2005; 65: 5578-87.
40. Viatour P, Dejardin E, Warnier M et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 2004; 16: 35-45.
41. Wang N, Thuraisingam T, Fallavollita L, Ding A, Radzioch D, Brodt P. The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res 2006; 66: 3062-70.
42. Devoogdt N, Revets H, Kindt A, Liu YQ, De Baetselier P, Ghassabeh GH. The tumor-promoting effect of TNF-α involves the induction of secretory leukocyte protease inhibitor. J Immunol 2006; 177: 8046-52.
43. Sugino T, Yamaguchi T, Ogura G et al. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol 2007; 212: 152-60.
44. Nukiwa T, Suzuki T. Effect of tobacco smoke in the intracellular trafficking of type II alveolar epithelial cells. Smoking Res Foundation Annu Res Report 2004; 10: 409-14.
45. Sato T, Takahashi S, Mizumoto T et al. Neutrophil elastase and cancer. Surg Oncol 2006; 15: 217-22.